Stuart D. Russell

Stuart D. Russell

Auto-generated profile, based on publicly available information

Stuart D. Russell

Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SRStuart D. Russell
Stuart D. Russell
KBKimberly L. Blackwell
Kimberly L. Blackwell
JLJulia Lawrence
Julia Lawrence
JPJohn E. Pippen
John E. Pippen
MRMatthew T. Roe
Matthew T. Roe
KMKenneth W. Mahaffey
Kenneth W. Mahaffey
Purpose: An independent Adjuvant Cardiac Review and Evaluation Committee (ACREC) systematically reviewed cases of symptomatic heart failure events to uniformly define the cardiac event rate across two large trials (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-31 and North Central Cancer Treatment Group [NCCTG] N9831) that assessed the addition of trastuzumab to standard adjuvant chemotherapy. Patients and Methods: The committee was composed of six independent oncologists and cardiologists. A retrospective review of patients with a cardiac event was performed by the primary investigators of the trials. The ACREC prospectively established criteria for determining a symptomatic heart failure event. Recovery status was determined from documented resolution of signs and symptoms. Potential risk factors were also assessed. Results: Medical records for a total of 173 patients were reviewed: 40 in the chemotherapy-alone arm and 133 in the trastuzumab arm. Trastuzumab-treated patients had a 2.0% incidence of symptomatic heart failure events compared with 0.45% in the chemotherapy-alone arm. Complete or partial recovery was observed in 86.1% of trastuzumab-treated patients with symptomatic heart failure events. Of five patients who died, only one patient had received trastuzumab. Independent predictors for cardiac events were age older than 50 years, a low ejection fraction at the start of paclitaxel treatment, and trastuzumab treatment. Conclusion: The incidence of symptomatic heart failure events is 2.0% in patients treated with adjuvant trastuzumab, and the majority of these patients recover with appropriate treatment.

8 December 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
SRStuart D Russell
Stuart D Russell
JRJoseph G Rogers
Joseph G Rogers
CMCarmelo A Milano
Carmelo A Milano
DDDavid B Dyke
David B Dyke
FPFrancis D Pagani
Francis D Pagani
HIHeartMate II Clinical Investigators
HeartMate II Clinical Investigators
Background— The effects of continuous blood flow and reduced pulsatility on major organ function have not been studied in detail. Methods and Results— We evaluated renal (creatinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) advanced heart failure patients who had been supported with the HeartMate II continuous-flow left ventricular assist device for bridge to transplantation. To determine whether patients with impaired renal and hepatic function improve over time with continuous-flow left ventricular assist device support or whether there are any detrimental effects in patients with normal organ function, we divided patients into those with above-normal and normal laboratory values before implantation and measured blood chemistry over time during left ventricular assist device support. There were significant improvements over 6 months in all parameters in the above-normal groups, with values in the normal groups remaining in the normal range over time. Mean blood urea nitrogen and serum creatinine in the above-normal groups decreased significantly from 37±14 to 23±10 mg/dL ( P <0.0001) and from 1.8±0.4 to 1.4±0.8 mg/dL ( P <0.01), respectively. There were decreases in aspartate transaminase and alanine transaminase in the above-normal groups from 121±206 and 171±348 to 36±19 and 31±22 IU ( P <0.001), respectively. Total bilirubin for the above-normal group was 2.1±0.9 mg/dL at baseline; after an acute increase at week 1, it decreased to 0.9±0.5 mg/dL by 6 months ( P <0.0001). Both renal and liver values from patients in the normal groups remained normal during support with the left ventricular assist device. Conclusions— The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period. Clinical Trial Registration Information— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00121472.

1 July 2013 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
MBMosi K. Bennett
Mosi K. Bennett
NGNisha A. Gilotra
Nisha A. Gilotra
CHColleen Harrington
Colleen Harrington
SRShaline Rao
Shaline Rao
JDJustin M. Dunn
Justin M. Dunn
SRStuart D. Russell
Stuart D. Russell
Background—: Endomyocardial biopsy (EMB) is often considered when the pathogenesis of heart failure cannot be determined by noninvasive testing. Uncertainty remains about the diagnostic and clinical use of EMB in various clinical scenarios. Methods and Results—: We examined the characteristics of a cohort of patients with unexplained heart failure who underwent EMB at a tertiary care medical center. We categorized each patient into a clinical scenario as outlined by the 2007 AHA/ACC/ESC guidelines and determined the number of times EMB provided a diagnosis or altered the clinical course. A total of 851 patients underwent EMB from 2000–2009. Overall, 25.5% of EMBs provided a diagnosis and 22.7% of EMBs changed clinical course. Heart failure associated with unexplained restrictive cardiomyopathy was the most common clinical scenario, comprising 33.6% (286/851) of EMBs, and 84 (29.4%) of these EMBs were diagnostic. EMB for unexplained heart failure of <2 weeks duration had a diagnostic yield at 35% (39/109). There were 4 uncommon scenarios where EMB had a high diagnostic and clinical yield. There were 16 complications for an overall rate of 1.9%. Conclusions—: We confirm that EMB is useful in acute onset unexplained cardiomyopathy. We demonstrate a role for EMB in suspected infiltrative disease and in the management of rare clinical scenarios, such as suspected hypersensitivity myocarditis, anthracycline cardiomyopathy, cardiac tumors, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Our results suggest low use of EMB in chronic heart failure that responds to usual care.

1 September 2008 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DBDaniel R. Bensimhon
Daniel R. Bensimhon
ELEric S. Leifer
Eric S. Leifer
SEStephen J. Ellis
Stephen J. Ellis
JFJerome L. Fleg
Jerome L. Fleg
SKSteven J. Keteyian
Steven J. Keteyian
SRStuart D. Russell
Stuart D. Russell

1 October 2009 in American Heart Journal
Verified
Journal Article
Closed access
SRStuart D. Russell
Stuart D. Russell
MSMatthew A. Saval
Matthew A. Saval
JRJennifer L. Robbins
Jennifer L. Robbins
MEMyrvin H. Ellestad
Myrvin H. Ellestad
SGStephen S. Gottlieb
Stephen S. Gottlieb
BCBleakley Chandler
Bleakley Chandler

1 November 2008 in Congestive Heart Failure
Verified
Journal Article
Open access
PDF file
SRStuart D. Russell
Stuart D. Russell
LMLeslie W. Miller
Leslie W. Miller
FPFrancis D. Pagani
Francis D. Pagani
Despite improvements in medical therapy for heart failure, more than 250,000 people die in the United States as a result of heart failure each year. There are multiple risk factors and models that have been created to identify these people, yet there has not been a significant impact on outcomes or change in the therapies for these patients. The authors review the available therapies for patients with advanced heart failure and the various risk models available to predict morbidity and mortality and present simple “office predictors” that could be used to potentially predict patients who would benefit from these therapies.